What were the key revenue drivers for Intuitive Surgical in 2007?

The primary revenue drivers were the sales of da Vinci Surgical Systems and the recurring revenue generated from instruments, accessories, and service contracts. The increase in system unit sales, coupled with higher average selling prices for newer models like the da Vinci S and the da Vinci S HD, significantly boosted product revenue. Growth in the installed base also contributed to increased service revenue.

How does Intuitive Surgical manage its research and development (R&D) investments?

Intuitive Surgical made substantial investments in R&D, with expenses totaling $48.9 million in 2007, an increase from $29.8 million in 2006. These investments focus on product improvements, development of new surgical procedures, and exploration of new technologies. The company also engages in co-development arrangements with partners to advance R&D efforts.

What are the main risks highlighted in the 10-K filing?

Key risks include the potential lack of market acceptance for da Vinci surgery, intense competition from established and emerging technologies, long and variable sales cycles for capital equipment, manufacturing challenges, reliance on sole or single-source suppliers, product liability claims, and the impact of regulatory approvals and third-party reimbursement.

How is Intuitive Surgical addressing international markets?

International sales accounted for 22% of total revenue in 2007. The company markets its products internationally through a combination of sales representatives and distributors. It also reorganized its international headquarters from France to Switzerland during 2007 to streamline operations and optimize its tax structure.

ISRG 10-K FY2007 Annual Report — Revenue, Net Income, EPS

Summary

Intuitive Surgical, Inc. (ISRG) demonstrated robust financial performance in its 2007 10-K filing, highlighted by significant revenue growth driven by the increasing adoption of its da Vinci Surgical System. The company reported a 61% increase in revenue to $600.8 million, with recurring revenue from instruments and accessories growing by 66%. This growth was fueled by a 42% increase in system unit sales and the successful introduction of new products like the da Vinci S Surgical System with HD vision. The company's strategy to establish da Vinci surgery as the standard for complex procedures is showing traction, particularly in urologic and gynecologic surgeries, with prostatectomies and hysterectomies being key drivers. ISRG continues to invest in research and development, indicating a commitment to technological advancement and market leadership. The company's strong cash position and operational efficiency provide a solid foundation for future growth, despite facing competitive pressures and the inherent complexities of regulatory approvals and long sales cycles in the medical device industry.

Financial Highlights

27 data points

Beta

Revenue

$600.83M

0.7% Gross Margin

Net Income

$144.54M

0.2% Net Margin

EPS (Diluted)

$0.41

Cash & Equivalents

$122.80M

Free Cash Flow

$205.69M

Financial Statements

Beta

Revenue	$600.83M
Cost of Revenue	$186.54M
Gross Profit	$414.29M
R&D Expenses	$48.86M
SG&A Expenses	$158.69M
Operating Expenses	$207.54M
Operating Income	$206.74M
Net Income	$144.54M
EPS (Basic)	$0.42
EPS (Diluted)	$0.41
Shares Outstanding (Basic)	340.48M
Shares Outstanding (Diluted)	351.19M

Key Highlights

1Revenue grew 61% to $600.8 million in 2007, up from $372.7 million in 2006.
2Recurring revenue (instruments, accessories, and services) increased 66% to $276.4 million, representing 46% of total revenue.
3241 da Vinci Surgical Systems were sold in 2007, a 42% increase from 170 systems sold in 2006.
4Operating income increased by 93% to $206.7 million, with operating margin improving to 34% of revenue from 29% in 2006.
5The company ended 2007 with a strong cash, cash equivalents, and investments balance of $635.4 million.
6da Vinci Prostatectomy (dVP) procedures accounted for over half of all procedures in 2007, with significant growth in da Vinci Hysterectomy (dVH) procedures.
7Stock-based compensation expense, a non-cash charge, was $36.3 million in 2007, impacting reported net income.

INTUITIVE SURGICAL INC Annual Report, Year Ended Dec 31, 2007

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions